ORATROPE Trademark

Trademark Overview

On Wednesday, December 2, 2015, a trademark application was filed for ORATROPE with the United States Patent and Trademark Office. The USPTO has given the ORATROPE trademark a serial number of 86837065. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 29, 2019. This trademark is owned by Ammonett Pharma LLC. The ORATROPE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical for enhancing growth hormone secretion
oratrope

General Information

Serial Number86837065
Word MarkORATROPE
Filing DateWednesday, December 2, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 29, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 3, 2016

Trademark Statements

Goods and ServicesPharmaceutical for enhancing growth hormone secretion

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, December 7, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLUMOS PHARMA, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressAUSTIN, TX 78756
Party NameAmmonett Pharma LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMidlothian, VA 23113
Party NameAmmonett Pharma LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMidlothian, VA 23113

Trademark Events

Event DateEvent Description
Monday, July 29, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 29, 2019ABANDONMENT - NO USE STATEMENT FILED
Tuesday, November 6, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 5, 2018EXTENSION 5 GRANTED
Monday, October 29, 2018EXTENSION 5 FILED
Monday, November 5, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, October 29, 2018TEAS EXTENSION RECEIVED
Tuesday, September 4, 2018ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, September 4, 2018TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, August 15, 2018AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, June 22, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 20, 2018EXTENSION 4 GRANTED
Wednesday, June 20, 2018EXTENSION 4 FILED
Wednesday, June 20, 2018TEAS EXTENSION RECEIVED
Friday, December 22, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 20, 2017EXTENSION 3 GRANTED
Wednesday, December 20, 2017EXTENSION 3 FILED
Wednesday, December 20, 2017TEAS EXTENSION RECEIVED
Friday, June 30, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 28, 2017EXTENSION 2 GRANTED
Wednesday, June 28, 2017EXTENSION 2 FILED
Wednesday, June 28, 2017TEAS EXTENSION RECEIVED
Tuesday, December 27, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 23, 2016EXTENSION 1 GRANTED
Friday, December 23, 2016EXTENSION 1 FILED
Friday, December 23, 2016TEAS EXTENSION RECEIVED
Tuesday, June 28, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 3, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 3, 2016PUBLISHED FOR OPPOSITION
Wednesday, April 13, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 22, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 21, 2016ASSIGNED TO EXAMINER
Monday, December 7, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, December 5, 2015NEW APPLICATION ENTERED IN TRAM

Related Keywords

oratrope secretion hormone growth enhancing pharmaceutical